Neurotrophic Tyrosine Kinase, Receptor, Type 1 (NTRK1) (Extracellular Domain) antibody

Details for Product No. ABIN351063
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

 
Antigen
Synonyms MTC, TRK, TRK1, TRKA, Trk-A, p140-TrkA, Tkr, trk, TrkA, C80751, Trk, CTRKA, trkA, trka
Epitope
Extracellular Domain
(28), (23), (16), (15), (15), (15), (13), (12), (12), (12), (12), (12), (12), (12), (10), (8), (7), (7), (4), (3), (3), (3), (2), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Reactivity
Mouse (Murine)
(259), (168), (164), (29), (29), (12), (12), (1)
Host
Rabbit
(249), (19), (3), (2)
Clonality
Polyclonal
Conjugate
Un-conjugated
(7), (6), (6), (6), (6), (6), (6), (6), (6), (6), (6), (2), (1), (1), (1), (1), (1), (1)
Application
Immunohistochemistry (IHC), Western Blotting (WB)
(154), (119), (60), (56), (40), (32), (31), (25), (15), (4), (3), (1)
Pubmed 10 references available
Catalog no. ABIN351063
Quantity 500 µg
Price
454.67 $   Plus shipping costs $45.00
Options
Shipping to United States (Change)
Availability Will be delivered in 7 to 8 Business Days

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen A synthetic peptide from the extracellular domain of human TrkA (High affinity nerve growth factor receptor, NTRK1, p140-TrkA, Trk-A) conjugated to an immunogenic carrier protein was used as the immunogen.
Specificity Specific for ISLR2.
Purification IgG
Alternative Name TrkA (High affinity nerve growth factor receptor, NTRK1, p140-TrkA, Trk-A)
Background Function: Required for high-affinity binding to nerve growth factor (NGF), neurotrophin-3 and neurotrophin-4/5 but not brain-derived neurotrophic factor (BDNF). Known substrates for the Trk receptors are SHC1, PI 3-kinase, and PLC-gamma-1. Has a crucial role in the development and function of the nociceptive reception system as well as establishment of thermal regulation via sweating. Activates ERK1 by either SHC1- or PLC-gamma-1-dependent signaling pathway.
Catalytic activity: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.
Subunit: Exists in a dynamic equilibrium between monomeric (low affinity) and dimeric (high affinity) structures. Binds SH2B2. Interacts with SQSTM1 which bridges NTRK1 to NGFR. Interacts with NGFR and ARMS. Can form a ternary complex with NGFR and ARMS and this complex is affected by the expression levels of ARMS. An increase in ARMS expression leads to a decreased association of NGFR and NTRK1.
Subcellular location: Cell membrane, Single-pass type I membrane protein. Note: Endocytosed to the endosomes upon treatment of cells with NGF.
Tissue specificity: Isoform Trka-II is primarily expressed in neuronal cells, isoform Trka-I is found in non-neuronal tissues. Also known as: High affinity nerve growth factor receptor, NTRK1, p140-TrkA, Trk-A, Neurotrophic tyrosine kinase receptor type 1, Slow nerve growth factor receptor.
UniProt Q5RKR3
Application Notes A concentration of 10-50 µg/mL is recommended.
The optimal concentration should be determined by the end user.
Restrictions For Research Use only
Format Lyophilized
Reconstitution Reconstitute in 500 µL of sterile water. Centrifuge to remove any insoluble material.
Handling Advice Avoid freeze and thaw cycles.
Storage -20 °C
Storage Comment Maintain the lyophilised/reconstituted antibodies frozen at -20 °C for long term storage and refrigerated at 2-8 °C for a shorter term. When reconstituting, glycerol (1:1) may be added for an additional stability.
Expiry Date 12 months
General Klein, Jing, Nanduri et al.: "The trk proto-oncogene encodes a receptor for nerve growth factor." in: Cell, Vol. 65, Issue 1, pp. 189-97, 1991 (PubMed).

Hempstead, Martin-Zanca, Kaplan et al.: "High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low-affinity NGF receptor." in: Nature, Vol. 350, Issue 6320, pp. 678-83, 1991 (PubMed).

Martin-Zanca, Hughes, Barbacid: "A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences." in: Nature, Vol. 319, Issue 6056, pp. 743-8, 1986 (PubMed).

Martin-Zanca, Oskam, Mitra et al.: "Molecular and biochemical characterization of the human trk proto-oncogene." in: Molecular and cellular biology, Vol. 9, Issue 1, pp. 24-33, 1989 (PubMed).

Loeb, Stephens, Copeland et al.: "A Trk nerve growth factor (NGF) receptor point mutation affecting interaction with phospholipase C-gamma 1 abolishes NGF-promoted peripherin induction but not neurite outgrowth." in: The Journal of biological chemistry, Vol. 269, Issue 12, pp. 8901-10, 1994 (PubMed).

Shelton, Sutherland, Gripp et al.: "Human trks: molecular cloning, tissue distribution, and expression of extracellular domain immunoadhesins." in: The Journal of neuroscience : the official journal of the Society for Neuroscience, Vol. 15, Issue 1 Pt 2, pp. 477-91, 1995 (PubMed).

Stephens, Loeb, Copeland et al.: "Trk receptors use redundant signal transduction pathways involving SHC and PLC-gamma 1 to mediate NGF responses." in: Neuron, Vol. 12, Issue 3, pp. 691-705, 1994 (PubMed).

Indo, Mardy, Tsuruta et al.: "Structure and organization of the human TRKA gene encoding a high affinity receptor for nerve growth factor." in: The Japanese journal of human genetics, Vol. 42, Issue 2, pp. 343-51, 1997 (PubMed).

Fujimoto, Kitazawa, Maeda et al.: "Methylation adjacent to negatively regulating AP-1 site reactivates TrkA gene expression during cancer progression." in: Oncogene, Vol. 24, Issue 32, pp. 5108-18, 2005 (PubMed).

Gregory, Barlow, McLay et al.: "The DNA sequence and biological annotation of human chromosome 1...." in: Nature, Vol. 441, Issue 7091, pp. 315-21, 2006 (PubMed).

Hosts (249), (19), (3), (2)
Reactivities (259), (168), (164), (29), (29), (12), (12), (1)
Applications (154), (119), (60), (56), (40), (32), (31), (25), (15), (4), (3), (1)
Conjugates (7), (6), (6), (6), (6), (6), (6), (6), (6), (6), (6), (2), (1), (1), (1), (1), (1), (1)
Epitopes (28), (23), (16), (15), (15), (15), (13), (12), (12), (12), (12), (12), (12), (12), (10), (8), (7), (7), (4), (3), (3), (3), (2), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
back to top